Collplant Holdings (CLGN) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
CollPlant Biotechnologies reported Q1 2024 financial results, noting a net loss increase and a cash balance of $23.2 million. The company highlighted its advancements in regenerative breast implants and ESG commitments, alongside a patent grant for its photocurable dermal filler product. Ongoing large-animal trials and development partnerships, such as with AbbVie, signal CollPlant’s continued innovation in regenerative and aesthetic medicine.
For further insights into CLGN stock, check out TipRanks’ Stock Analysis page.
